Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02593162 · ClinicalTrials.gov registry record · Phase 2
A Study of Faldaprevir, Ribavirin and TD-6450 in Participants With Genotype 4 Hepatitis C Virus Infection
A Phase 2 study, sponsored by Trek Therapeutics, PBC.
- Completed
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT02593162 is a Phase 2 study that has completed, run by Trek Therapeutics, PBC. The registered enrollment target is 16 participants.
The verdict
NCT02593162, a Phase 2 study, has completed, sponsored by Trek Therapeutics, PBC.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
Phase 2a study designed to assess the safety, efficacy, and pharmacokinetics of Faldaprevir and TD-6450 in combination with Ribavirin for a 12-week treatment duration in treatment-naïve participants with genotype 4 hepatitis C virus (HCV) infection.
Interventions
- DRUG Ribavirin
- DRUG TD-6450
- DRUG Faldaprevir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2015-10 |
| Est. Completion | 2016-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02593162
The ClinicalTrials.gov registry entry for NCT02593162 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Trek Therapeutics, PBC, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Ribavirin is the first listed.
NCT02593162 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02593162 about?
NCT02593162 is a clinical study titled "A Study of Faldaprevir, Ribavirin and TD-6450 in Participants With Genotype 4 Hepatitis C Virus Infection". Phase 2a study designed to assess the safety, efficacy, and pharmacokinetics of Faldaprevir and TD-6450 in combination with Ribavirin for a 12-week treatment duration in treatment-naïve participants with genotype 4 hepatitis C virus (HCV) infection.
What is the current status of trial NCT02593162?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2015-10. Estimated completion is 2016-12.
What interventions are being tested in trial NCT02593162?
The interventions under investigation include: Ribavirin (DRUG), TD-6450 (DRUG), Faldaprevir (DRUG).
Who is sponsoring clinical trial NCT02593162?
This trial is sponsored by Trek Therapeutics, PBC, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.